UCB RECEIVES U.S. FDA BREAKTHROUGH THERAPY DESIGNATION FOR CIMZIA®(CERTOLIZUMAB PEGOL) IN PREGNANT WOMEN WITH ANTIPHOSPHOLIPID SYNDROME (APS)

Reuters · 1d ago

Please log in to view news